ArticleHuman vaccines & immunotherapeutics2026
Trends in HPV vaccination among adults aged 27-45 years in the United States.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite expanded human papillomavirus (HPV) vaccination recommendations via shared clinical decision-making (SCDM) for adults aged 27-45 years (i.e., mid-adults), uptake remains low in the United States. Examining trends in HPV vaccination under SCDM across sociodemographic groups, vaccination sites, provider types, and geographical regions can offer insights into SCDM guideline implementation for HPV vaccination in eligible mid-adults. A retrospective cohort study was conducted using the Merative MarketScan® commercial claims database (2006-2023) to evaluate HPV vaccination uptake among mid-adults (aged 27-45 years). Annual and cumulative HPV vaccination rates (2019-2023) were analyzed overall and stratified by sociodemographic characteristics, provider type, and vaccination setting. Among the 3 to 4 million annually unvaccinated eligible adults aged 27-45 years identified in the database, the annual rate of HPV vaccination initiation rose modestly from 0.21% in 2019 to 0.54% in 2023 (5-year cumulative vaccination uptake: 0.84%). Most HPV vaccinations occurred in provider offices, though the proportion administered in pharmacies increased over time while the proportion in provider offices declined. Geographic variability in HPV vaccine uptake was substantial, with state-level rates ranging from 0.23% to 1.56%. These findings indicate that HPV vaccination uptake among mid-adults in the US remains low. Further research is needed to characterize geographic and sex-based variation in adult HPV vaccination and to further explore the growing role of pharmacies as HPV vaccination sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.